Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Last Updated: November 10, 2016; Last Reviewed: June 26, 2019
Treating Mild Infections (Such As Focal Pneumonia or Asymptomatic Patients with Positive Serology and CD4 count <250 cells/mm3)Preferred Therapy:
Treating Bone or Joint InfectionsPreferred Therapy:
Treating Severe, Non-Meningeal Infection (Diffuse Pulmonary or Severely Ill Patients with Extrathoracic Disseminated Disease)—Acute PhasePreferred Therapy:
Treatment For Meningeal Infections (Consultation With A Specialist Is Advised)Preferred Therapy:
|Duration of Therapy
Focal Coccidioidal Pneumonia, or Asymptomatic Patients with Positive Serology and CD4 count <250 cells/mm3, Therapy Can Be Stopped If (AII):
* It should be noted that all of the triazole antifungals have the potential for complex, and possibly bidirectional, interactions with drugs that are principally based on CYP 3A4 enzyme for metabolism. Therapeutic drug monitoring and dosage adjustments, may be necessary. Clinicians should refer to Table 5 for dosage guidance when triazoles are used with other drugs for treatment of OI, and to the antiretroviral treatment guidelines for interaction recommendations with ARV, especially when used with efavirenz, ritonavir- or cobicistat-containing regimens.
Key to Acronyms: CD4 = CD4 T lymphocyte cell; CSF = cerebrospinal fluid; IgG = immunogloblulin G; IgM = immunoglobulin M; IV = intravenous; PO = orally
- CDC | 2015 STD Treatment Guidelines
- HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
- AIDSinfo Patient Materials: What is an Opportunistic Infection?
- AIDSource | HIV-Related Conditions
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Adult and Adolescent OI Guidelines Archive